Sonmez Alper, Yilmaz Mahmut Ilker, Korkmaz Ahmet, Topal Turgut, Caglar Kayser, Kaya Ayper, Eyileten Tayfun, Yenicesu Mujdat, Oguz Yusuf, Basal Seref, Ipcioglu Osman Metin, Vural Abdulgaffar
Department of Internal Medicine, Gülhane School of Medicine, Etlik, 06018, Ankara, Turkey.
Department of Nephrology, Gülhane School of Medicine, Etlik, 06018, Ankara, Turkey.
Clin Exp Nephrol. 2008 Apr;12(2):110-118. doi: 10.1007/s10157-007-0017-2. Epub 2008 Jan 5.
Oxidative stress plays a role in the mechanism of chronic kidney disease (CKD), and antioxidant regimes are regarded as promising treatment modalities. We compared the effects of cilazapril, simvastatin, and hyperbaric oxygen (HBO) treatment on proteinuria and on oxidative stress in adriamycine (ADR)-induced proteinuria.
Seventy male Sprague-Dawley rats were housed, and 60 were injected with ADR to induce nephrosis. After the stabilization of proteinuria, rats were treated for 6 weeks with simvastatin (n = 10, 4 mg/kg/day), cilazapril (n = 10, 10 mg/kg/day), HBO (n = 10, 2.8 athmosphere absolute, 90 min/daily), HBO + cilazapril (n = 10), HBO + simvastatin (n = 10), and vehicle (n = 10). After euthanization at 12 weeks, protein carbonyl (PCO), superoxide dismutase (SOD), and glutathion peroxidase (GPx) levels were analyzed from tissues. The histological alterations in the kidneys were determined by semiquantitative scoring.
Protein carbonyl (PCO) levels were higher (p < 0.001), and the GPx and SOD levels were lower (p < 0.001 for all) in the nephrotic rats. Proteinuria was correlated to PCO (r = 0.483), GPx (r = -0.686), or SOD (r = -0.620) (p < 0.001 for all). Superoxide dismutase (SOD) (beta = -0.381, p = 0.02) and GPx (beta = -0.509, p < 0.001) were independently related to proteinuria levels. Both cilazapril and simvastatin significantly improved GPx, SOD, PCO, and proteinuria. When HBO was combined with either drug, the above markers further improved (p < 0.001). Both regimens caused distinct histological features, while the combination of HBO made much significant histological improvement.
Both cilazapril and simvastatin regimens improve oxidative stress and proteinuria, while the effects significantly increase with the combination of HBO treatment. HBO seems to be a candidate antioxidant strategy in glomerular diseases.
氧化应激在慢性肾脏病(CKD)的发病机制中起作用,抗氧化疗法被认为是有前景的治疗方式。我们比较了西拉普利、辛伐他汀和高压氧(HBO)治疗对阿霉素(ADR)诱导的蛋白尿及氧化应激的影响。
饲养70只雄性Sprague-Dawley大鼠,其中60只注射ADR诱导肾病。蛋白尿稳定后,大鼠分别接受辛伐他汀(n = 10,4 mg/kg/天)、西拉普利(n = 10,10 mg/kg/天)、HBO(n = 10,2.8个绝对大气压,每天90分钟)、HBO + 西拉普利(n = 10)、HBO + 辛伐他汀(n = 10)治疗6周,另10只大鼠接受赋形剂治疗。12周后安乐死,分析组织中的蛋白质羰基(PCO)、超氧化物歧化酶(SOD)和谷胱甘肽过氧化物酶(GPx)水平。通过半定量评分确定肾脏的组织学改变。
肾病大鼠的蛋白质羰基(PCO)水平较高(p < 0.001),而GPx和SOD水平较低(均p < 0.001)。蛋白尿与PCO(r = 0.483)、GPx(r = -0.686)或SOD(r = -0.620)相关(均p < 0.001)。超氧化物歧化酶(SOD)(β = -0.381,p = 0.02)和谷胱甘肽过氧化物酶(GPx)(β = -0.509,p < 0.001)与蛋白尿水平独立相关。西拉普利和辛伐他汀均显著改善了GPx、SOD、PCO和蛋白尿。当HBO与任一药物联合使用时,上述指标进一步改善(p < 0.001)。两种治疗方案均导致明显的组织学特征,而HBO联合治疗使组织学改善更为显著。
西拉普利和辛伐他汀治疗方案均能改善氧化应激和蛋白尿,而HBO联合治疗可显著增强疗效。HBO似乎是肾小球疾病中一种有潜力的抗氧化策略。